Open AccessTreatment of Moderate-to-Severe Psoriasis in the Presence of Kaposi’s Varicelliform Eruption
Author(s) -
Anna Campanati,
Elisa Molinelli,
Valerio Brisigotti,
Donatella Brancorsini,
Ivan Bobyr,
Federico Diotallevi,
Giulia Radi,
Annamaria Offidani
Publication year - 2019
Publication title -
case reports in dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.338
H-Index - 18
ISSN - 1662-6567
DOI - 10.1159/000501992
Subject(s) - psoriasis , medicine , erythroderma , clearance , dermatology , methotrexate , vaccinia , secukinumab , pustular psoriasis , generalized pustular psoriasis , acitretin , plaque psoriasis , sepsis , immunology , psoriatic arthritis , urology , recombinant dna , biochemistry , chemistry , gene
Kaposi’s varicelliform eruption (KVE) is a disseminated cutaneous infection usually induced by herpesvirus type 1 or 2, vaccinia virus or Coxsackie A16 virus in a patient with an underlying dermatosis. Risk factors for KVE reported in the literature include erythroderma, systemic sepsis, therapy with immunosuppressants such as methotrexate and systemic steroids, and therapy with systemic retinoids. The occurrence of KVE in psoriasis is rare and it predominantly appears in patients affected by erythrodermic psoriasis during immunosuppressive treatment. We report our experience of a remarkable case of a patient affected by severe erythrodermic psoriasis and KVE that healed after antiviral treatment and after having received secukinumab. After 1 year, psoriasis was cleared and no recurrence of KVE had occurred.